United Therapeutics (UTHR)
(Delayed Data from NSDQ)
$233.85 USD
-2.10 (-0.89%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $233.96 +0.11 (0.05%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth C Momentum C VGM
Cash flow Statements
Fiscal Year End for United Therapeutics Corporation falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | 984.80 | 727.30 | 475.80 | 514.80 | -104.50 |
Depreciation/Amortization & Depletion | 53.20 | 51.30 | 49.90 | 49.90 | 45.90 |
Net Change from Assets/Liabilities | -97.80 | -141.20 | -174.20 | 59.70 | -180.90 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 37.80 | 165.10 | 246.70 | 131.30 | 32.90 |
Net Cash From Operating Activities | 978.00 | 802.50 | 598.20 | 755.70 | -206.60 |
Property & Equipment | -230.40 | -138.80 | -120.80 | -56.90 | -83.70 |
Acquisition/ Disposition of Subsidiaries | -89.20 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -400.00 | -676.20 | -366.10 | -681.60 | -239.20 |
Other Investing Activities | 0.00 | 3.50 | 0.00 | 0.00 | -12.50 |
Net Cash from Investing Activities | -719.60 | -811.50 | -486.90 | -738.50 | -335.40 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 90.80 | 82.90 | 44.80 | 34.80 | 11.90 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | -100.00 | 0.00 | 0.00 | -50.00 | 600.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -2.70 | -7.50 | 0.00 | -1.70 | -0.70 |
Net Cash from Financing Activities | -11.90 | 75.40 | 44.80 | -16.90 | 611.20 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 246.50 | 66.40 | 156.10 | 0.30 | 69.20 |
Cash at Beginning of Period | 961.20 | 894.80 | 738.70 | 738.40 | 669.20 |
Cash at End of Period | 1,207.70 | 961.20 | 894.80 | 738.70 | 738.40 |
Diluted Net EPS | 19.81 | 15.00 | 10.06 | 11.54 | -2.39 |
Fiscal Year End for United Therapeutics Corporation falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | 984.80 | 767.70 | 500.10 | 240.90 |
Depreciation/Amortization & Depletion | NA | 53.20 | 39.50 | 26.20 | 13.30 |
Net Change from Assets/Liabilities | NA | -97.80 | -6.10 | -52.10 | 127.20 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 37.80 | 26.20 | 6.90 | -6.60 |
Net Cash From Operating Activities | NA | 978.00 | 827.30 | 481.10 | 374.80 |
Property & Equipment | NA | -230.40 | -151.70 | -86.00 | -41.30 |
Acquisition/ Disposition of Subsidiaries | NA | -89.20 | 0.00 | 0.00 | 0.00 |
Investments | NA | -400.00 | -610.00 | -362.30 | -179.80 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | -719.60 | -761.70 | -448.30 | -221.10 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 90.80 | 83.60 | 76.00 | 51.30 |
Issuance (Repayment) of Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | -100.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | -2.70 | -2.70 | -2.70 | -2.70 |
Net Cash from Financing Activities | NA | -11.90 | 80.90 | 73.30 | 48.60 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | 246.50 | 146.50 | 106.10 | 202.30 |
Cash at Beginning of Period | NA | 961.20 | 961.20 | 961.20 | 961.20 |
Cash at End of Period | NA | 1,207.70 | 1,107.70 | 1,067.30 | 1,163.50 |
Diluted Net EPS | NA | 4.33 | 5.38 | 5.24 | 4.86 |